Announcements Trials
Browse Landscape

Phase

Phase 1/2 4Phase 2 2Phase 1 1

Status

Recruiting 2Withdrawn 1Active not recruiting 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 4Thoracic 2Head & Neck 1Dermatologic 1

Conditions

Pancreatic Neoplasms 19Carcinoma, Non-Small-Cell Lung 13Breast Neoplasms 9Neoplasms 6Lung Neoplasms 5Neoplasm Metastasis 4Colorectal Neoplasms 4Breast Neoplasms, Male 4Squamous Cell Carcinoma of Head and Neck 3Melanoma 3Fallopian Tube Neoplasms 3Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Recurrence 2Ovarian Neoplasms 2Oropharyngeal Neoplasms 2Inflammatory Breast Neoplasms 2Carcinoma, Ovarian Epithelial 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Cancer, Papillary 1Solid Tumor 1Platinum-Refractory Fallopian Tube Carcinoma 1Pancreatic Ductal Adenocarcinoma 1Neoplasms, Squamous Cell 1Neoplasms, Glandular and Epithelial 1Neoplasms, Basal Cell 1Neoplasms by Site 1Neoplasms by Histologic Type 1

Interventions

Cetuximab 44Oxaliplatin 39Irinotecan 38Fluorouracil 36Capecitabine 36pembrolizumab 35Leucovorin 35Bevacizumab 35Nivolumab 21Gemcitabine 17regorafenib 13Panitumumab 12IFL protocol 12Folfox protocol 12Cyclophosphamide 12Pemetrexed 11Cisplatin 11tislelizumab 9Paclitaxel 9HMPL-013 9Carboplatin 9130-nm albumin-bound paclitaxel 8durvalumab 7Specimen Handling 7Docetaxel 7trametinib 6Trifluridine 6Ipilimumab 6Drug Therapy 6trifluridine tipiracil drug combination 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1/2 × Colorectal Neoplasms × Taxes × Clear all
NCT04083599 2026-06-02

GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors

Genmab

Phase 1/2 Active not recruiting
350 enrolled
DermatologicGastrointestinalHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma, Colorectal Neoplasms

NCT06385925 2026-04-24

A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation

Tyligand Pharmaceuticals (Suzhou) Limited

Phase 1/2 Recruiting
440 enrolled
GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT07259590 2025-12-02

A Study of GFH375 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors Harboring KRAS G12D Mutation

Genfleet Therapeutics (Shanghai) Inc.

Phase 1/2 Recruiting
126 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT03169777 2025-02-21

QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC

ImmunityBio, Inc.

Phase 1/2 Withdrawn
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡